alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 1236.1 Purpose.

This part addresses prudential management and operations standards that are required and authorized by 12 U.S.C. 4513b, including the establishment of Standards by Federal Housing Finance Agency (FHFA) and the processes by which FHFA can notify a regulated entity or the Office of Finance of its failure to operate in accordance with a Standard and direct the regulated entity or the Office of Finance to take corrective action. This part further specifies the possible consequences if any regulated entity or the Office of Finance fails to operate in accordance with an applicable Standard or otherwise fails to comply with this part.

[89 FR 3539, Jan. 19, 2024]
§ 74.14 Can an applicant or participant reapply for admission to the VIP Verification Program? ( a ) Once an application, an appeal of a denial of an application, or an appeal of a verified status cancellation has been denied, or a verified status cancellation which was not appealed has been issued, the applicant or participant shall be required to wait for a period of 6 months before a new application will be processed by CVE.
( b ) Participants may reapply prior to the termination of their eligibility period. If a participant is found to be ineligible, the participant will forfeit any time remaining on their eligibility period and will be immediately removed from the VIP Verification database. An applicant removed pursuant to this section may appeal the decision to OHA in accordance with § 74.13. The date of a new determination letter verifying an applicant will be the beginning of the next 3-year eligibility period.
[83 FR 48231, Sept. 24, 2018]
<PAGE>   1

                                                                    EXHIBIT 11.1

                   Lamar Advertising Company and Subsidiaries
                   Earnings Per Share Computation Information

                     Years ended October 31, 1995 and 1996,
                     the two months ended December 31, 1996
                      and the year ended December 31, 1997


<TABLE>
<CAPTION>
                                         Year Ended October 31       Two Months Ended    Year Ended
                                                                       December 31      December 31,
                                         1995             1996             1996            1997
                                      -----------     -----------      ------------     -----------
<S>                                   <C>              <C>              <C>               <C>
Net earnings (loss) applicable
    to common stock                   $10,698,000      10,484,000       (8,115,000)       2,476,000
                                      ===========     ===========      ===========      ===========

    Weighted average common
         shares outstanding            50,658,161      41,134,476       45,520,784       47,037,497

    Shares issuable upon exercise
          of stock options                     --         114,057               --          363,483

    Weighted average common
          shares and common
                                      -----------     -----------      -----------      -----------
          equivalents outstanding      50,658,161      41,248,533       45,520,784       47,400,980
                                      ===========     ===========      ===========      ===========

Net earnings (loss) per common
    share basic and diluted           $      0.21            0.25            (0.18)            0.05
                                      ===========     ===========      ===========      ===========

The above earnings per share (EPS) calculations are submitted in accordance with
Statement of Financial Accounting Standards No. 128. An EPS calculation in
accordance with Regulation S-K item 601 (b) (11)) is not shown above for the
two months ended December 31, 1996 because it produces an antidilutive result.
The following information is disclosed for purposes of calculating antidilutive
EPS for that period.

     Weighted average common
          shares outstanding                                            45,520,784

    Shares issuable upon exercise
         of stock options                                                  547,018
                                                                       -----------

    Weighted average common
         shares and common share
         equivalents outstanding                                        46,067,802
                                                                       ===========

    Net loss per common share                                          $     (0.18)
                                                                       ===========

</TABLE>
<PAGE>   1

                                                                     Exhibit 4.7

                                SECOND AMENDMENT
                                     TO THE
                              LOMAK PETROLEUM, INC.
                    1994 OUTSIDE DIRECTORS STOCK OPTION PLAN

         I, Jeffery A. Bynum, hereby certify that I am the Secretary of Lomak
Petroleum, Inc., (the "Company") and that, as such, I am authorized to execute
this amendment on behalf of the Company, and, DO HEREBY FURTHER CERTIFY THAT the
following resolution was duly approved and adopted by the Board of Directors of
the Company on August 21, 1996:

                  RESOLVED, that the Lomak Petroleum, Inc. 1994 Outside
Directors Stock Option plan be amended by deleting Section 1 thereof in its
entirety and substituting the following therefore:

 "SECTION 1.               PURPOSE OF THE PLAN.

                  The purpose of this Lomak Petroleum, Inc. 1994 Stock Option
         Plan for Outside Directors (the "Plan") is to strengthen the ability of
         Lomak Petroleum, Inc. (the "Company") to attract and to retain the
         services of experienced and knowledgeable independent individuals as
         members of the Board of the Company, to extend to them the opportunity
         to acquire a proprietary interest in the Company so that they will
         apply their best efforts for the benefit of the Company, and to provide
         those individuals with an additional incentive to continue in their
         position, for the best interest of the Company and its stockholders. In
         furtherance of such purpose, Eligible Directors (as defined below)
         shall each receive 6,000 Stock Options on June 1, 1994 and thereafter
         8,000 Stock Options per annum, subject to adjustment, for their service
         on the Board on the later of each June 1 or the fifth business day
         following the Annual Meeting of the Shareholders of the Company, that
         they are serving as an Eligible Director commencing June 1, 1995."

August 21, 1996

                                                   /s/ Jeffery A. Bynum
                                                 -------------------------------
                                                          Jeffery A. Bynum
                                                          Corporate Secretary


                                       11
HomeOffice of the SpokespersonPress Releases...Sanctioning PRC and Mexico Based Individuals and Entities for Enabling Illicit Drug Production

# 									Sanctioning PRC and Mexico Based Individuals and Entities for Enabling Illicit Drug Production							

Press Statement

Antony J. Blinken, Secretary of State

May 30, 2023

The United States is a leader in the global effort to stop the illicit manufacture and trafficking of illicit fentanyl and other synthetic drugs, a major cause of death among adults ages 18 to 45 in the United States.  Today, the Department of the Treasury sanctioned 17 individuals and entities involved in the production of illicit drugs, 13 of which are based in the People’s Republic of China (PRC), and four of which are based in Mexico.  This action was coordinated closely across the U.S. government with the Government of Mexico and targets entities and individuals involved in criminal activities, not specific countries.  These designated individuals and entities were involved in creating counterfeit pills with false markings of legitimate pharmaceuticals, often laced with fentanyl, and likely bound for U.S. markets.

Today’s actions further bolster those previously taken by the Biden-Harris administration as part of a whole-of-government offensive to save lives by disrupting illicit fentanyl supply chains around the globe. To date, the Administration has supported more than 20 million Americans in recovery, strengthened partnerships with law enforcement around the world to disrupt and dismantle transnational criminal organizations, and issued over 30 reward offers totaling over $75 million for information to help bring illicit fentanyl traffickers to justice through the Narcotics and Transnational Organized Crime Rewards Programs.  To address synthetic drug threats, the Department of State is mobilizing a global coalition that will strengthen international engagement and drive innovative actions.

This Administration remains committed to disrupting the illicit synthetic drugs supply chain, from production to smuggling to distribution.  I look forward to working with all willing countries around the world to address this shared threat.

Tags

Bureau of East Asian and Pacific AffairsBureau of International Narcotics and Law Enforcement AffairsBureau of Western Hemisphere AffairsChinaCombating Drugs and CrimeDivision for Counter Threat Finance and SanctionsDrug TraffickingMexicoOffice of the SpokespersonThe Secretary of State

Back to Top
<TABLE> <S> <C>

<PAGE>
<ARTICLE>           5
<LEGEND>
                    The Schedule contains summary financial
                    information extracted from the financial
                    statements for PruTech Research and
                    Development Partnership III and is qualified
                    in its entirety by reference to such
                    financial statements
</LEGEND>

<RESTATED>
<CIK>             0000794357
<NAME>            PruTech Research and Development Partnership III
<MULTIPLIER>      1

<FISCAL-YEAR-END>               Dec-31-1999

<PERIOD-START>                  Jan-1-1999

<PERIOD-END>                    Jun-30-1999

<PERIOD-TYPE>                   6-Mos

<CASH>                          1,095,266

<SECURITIES>                    0

<RECEIVABLES>                   0

<ALLOWANCES>                    0

<INVENTORY>                     0

<CURRENT-ASSETS>                1,095,266

<PP&E>                          0

<DEPRECIATION>                  0

<TOTAL-ASSETS>                  1,095,266

<CURRENT-LIABILITIES>           27,679

<BONDS>                         0

<PREFERRED-MANDATORY>           0

<PREFERRED>                     0

<COMMON>                        0

<OTHER-SE>                      1,067,587

<TOTAL-LIABILITY-AND-EQUITY>    1,095,266

<SALES>                         0

<TOTAL-REVENUES>                17,763

<CGS>                           0

<TOTAL-COSTS>                   0

<OTHER-EXPENSES>                53,359

<LOSS-PROVISION>                0

<INTEREST-EXPENSE>              0

<INCOME-PRETAX>                 0

<INCOME-TAX>                    0

<INCOME-CONTINUING>             0

<DISCONTINUED>                  0

<EXTRAORDINARY>                 0

<CHANGES>                       0

<NET-INCOME>                    (35,596)

<EPS-BASIC>                   (.78)

<EPS-DILUTED>                   0

</TABLE>
CUSTOMER SUPPORT VARIABLES

                                     between

                               THE BOEING COMPANY

                                       and

                            American Trans Air, Inc.


                   Supplemental Exhibit CS1 to Purchase Agreement Number 2285




<PAGE>


                           CUSTOMER SUPPORT VARIABLES

                                   relating to

                          BOEING MODEL 757-33N AIRCRAFT


Customer currently operates an aircraft of the same model as the Aircraft.  Upon
Customer's  request,  Boeing will  develop and  schedule a  customized  Customer
Support  Program to be  furnished  in support of the  Aircraft.  The  customized
program will be based upon and equivalent to the entitlements summarized below.

1.       MAINTENANCE TRAINING.
         --------------------

         1.1      Maintenance   Training  Minor  Model  Differences  Course,  if
                  required,   covering   operational,   structural   or  systems
                  differences between Customer's newly-purchased Aircraft and an
                  aircraft of the same model currently  operated by Customer;  1
                  class of 15 students;

         1.2      Training  materials,  if applicable,  will be provided to each
                  student. In addition, one set of training materials as used in
                  Boeing's  training  program,  including  visual aids, text and
                  graphics will be provided for use in  Customer's  own training
                  program.

2.       FLIGHT TRAINING.
         ---------------

         Boeing will provide,  if required,  one classroom course to acquaint up
         to 15 students with  operational,  systems and performance  differences
         between Customer's newly-purchased Aircraft and an aircraft of the same
         model currently operated by Customer.

         Any training  materials used in Flight Training,  if required,  will be
         provided for use in Customer's own training program.

3.       PLANNING ASSISTANCE.
         -------------------

         3.1      MAINTENANCE AND GROUND OPERATIONS.
                  ---------------------------------

                  Upon  request,   Boeing  will  provide   planning   assistance
                  regarding Minor Model Differences requirements for facilities,
                  tools and equipment.

         3.2      SPARES.
                  ------

                  Boeing will revise, as applicable,  the customized Recommended
                  Spares Parts List (RSPL) and Illustrated Parts Catalog (IPC).

4.       TECHNICAL DATA AND DOCUMENTS.
         ----------------------------

         Boeing  will  revise,  as  applicable,  technical  data  and  documents
         provided with previously delivered aircraft.
**Exhibit 32.2**

 

CERTIFICATION PURSUANTTO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Inconnection with the Quarterly Report on Form 10-Q of SkyWest, Inc.(the “Company”) for the quarter ended September 30, 2008 as filed with theSecurities and Exchange Commission on the date hereof (the “Report”), I,Bradford R. Rich, Chief Financial Officer of the Company, certify, pursuant to18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of2002, that, to the best of my knowledge:

 

(1)            TheReport fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and

 

(2)            Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 
| /s/ Bradford R. Rich    |   |
|-------------------------|--------|
|                    |   |
| Bradford R. Rich        |   |
| Chief Financial Officer |   |
| November 6, 2008   |   |

 

This certification accompanies the Report pursuantto Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except tothe extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by theCompany for purposes of Section 18 of the Securities Exchange Act of 1934,as amended.

 

A signed original of this written statement requiredby Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to theCompany and will be retained by the Company and furnished to the Securities andExchange Commission or its staff upon request.

 

----
# Antarctic Treaty – United States Department of State

- Antarctic Treaty &#8211; Notification of Deposit of Instrument; Saudi Arabia, May 22, 2024 Office of Treaty Affairs
- Antarctic Treaty &#8211; Notification of Deposit of Instrument; San Marino, February 14, 2023 Office of Treaty Affairs
- Antarctica &#8211; Antarctic Treaty &#8211; Notification of Deposit of Instrument; Costa Rica, August 11, 2022 Office of Treaty Affairs
- Antarctica &#8211; Annex V to Protocol on Environmental Protection &#8211; Notification of Deposit of Instrument; Canada, February 23, 2022 Office of Treaty Affairs
- Antarctica &#8211; Amendment of Annex II to Protocol on Environmental Protection &#8211; Notification of Deposit of Instrument; Canada, February 23, 2022 Office of Treaty Affairs
- Antarctica &#8211; Amendment of Annex II to Protocol on Environmental Protection &#8211; Notification of Deposit of Instrument; Canada &#8211; February 23, 2022 Office of Treaty Affairs
- Antarctic Treaty &#8211; Protocol on Environmental Protection &#8211; Notification of Deposit of Instrument; Colombia &#8211; Feb. 13, 2020 Office of Treaty Affairs
- Antarctica: Annex V to Protocol on Environmental Protection &#8211; Notification of Deposit of Instrument; Canada February 23, 2022 Office of Treaty Affairs
- Antarctic Treaty &#8211; Notification of Deposit of Instrument; Slovenia, April 22, 2019 Office of Treaty Affairs
[Federal Register Volume 74, Number 189 (Thursday, October 1, 2009)]
[Notices]
[Page 50805]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-23725]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Eunice Kennedy Shriver National Institute of Child Health and 
Human Development; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel; Instruments and Devices for the 
Neonatal Intensive Care Units.
    Date: November 2, 2009.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Neelakanta Ravindranath, PhD, Scientific Review 
Officer, Division of Scientific Review, Eunice Kennedy Shriver 
National Institute, of Child Health and Human Development, 6100 
Executive Blvd., Room 5B01G, Bethesda, MD 20892-7510, 301-435-6889.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: September 25, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-23725 Filed 9-30-09; 8:45 am]
BILLING CODE 4140-01-P
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 08-6318

KENT BRUMMELL, Petitioner - Appellant,
v. KATHLEEN GREEN, Warden; DOUGLAS F. GANSLER, Attorney General of the State of Maryland, Respondents - Appellees.
Appeal from the United States District Court for the District of Maryland, at Baltimore. William D. Quarles, Jr., District Judge. (1:07-cv-02470-WDQ) Submitted: September 12, 2008 Decided: November 7, 2008 Before MICHAEL and KING, Circuit Judges, and HAMILTON, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. Kent Brummell, Appellant Pro Se. Edward John Kelley, OFFICE OF THE ATTORNEY GENERAL OF MARYLAND, Baltimore, Maryland, for Appellee. Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Kent Brummell seeks to appeal the district court’s order dismissing as untimely his 28 U.S.C. § 2254 (2000) petition. The order is not appealable unless a circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (2000). A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by demonstrating that reasonable jurists would find that any assessment of the constitutional claims by the district court is debatable or wrong and that any dispositive procedural ruling by the district court is likewise debatable. Miller-El v. Cockrell , 537 U.S. 322, 336-38 (2003); Slack v. McDaniel , 529 U.S. 473, 484 (2000); Rose v. Lee , 252 F.3d 676, 683-84 (4th Cir. 2001). We have independently reviewed the record and conclude that Brummell has not made the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process. DISMISSED
#### § 1807.502 CMF Award limits.

An eligible Applicant and its Subsidiaries and Affiliates may not be awarded more than 15 percent of the aggregate funds available for the CMF Awards during any year.
# C_2016048EN.01009501.xml

| 8.2.2016 | EN | Official Journal of the European Union | C 48/95 |
| --- | --- | --- | --- |

8.2.2016

EN

Official Journal of the European Union

C 48/95

---

Judgment of the Civil Service Tribunal (Second Chamber) of 16 December 2015 — DE v EMA

(Case F-135/14) (1)

1

((Civil service - EMA staff - Placement on ‘non-active status’ - Act adversely affecting an official or staff member - Right to be heard - Infringement))

(2016/C 048/107)

Language of the case: English

Parties

Parties

Applicant: DE (represented by: S. Rodrigues and A. Blot, lawyers)

Applicant:

Defendant: European Medicines Agency (represented by: S. Marino, T. Jabłoński and N. Rampal Olmedo, acting as Agents, assisted by D. Waelbroeck and A. Duron, lawyers)

Defendant:

Re:

Re:

Application for annulment of the EMA’s decision to suspend the applicant from duty and a request for compensation for the non-material harm which he claims to have suffered.

Operative part of the judgment

Operative part of the judgment

The Tribunal:

| 1. | Annuls the decision of 31 January 2014 by which the European Medicines Agency placed DE on ‘non-active status’; |
| --- | --- |

1.

Annuls the decision of 31 January 2014 by which the European Medicines Agency placed DE on ‘non-active status’;

| 2. | Orders the European Medicines Agency to pay DE the sum of EUR 10 000; |
| --- | --- |

2.

Orders the European Medicines Agency to pay DE the sum of EUR 10 000;

| 3. | Orders the European Medicines Agency to bear its own costs and to pay the costs incurred by DE. |
| --- | --- |

3.

Orders the European Medicines Agency to bear its own costs and to pay the costs incurred by DE.

---

(1)  OJ C 16, 19/1/2015, p. 50.

1

---
#### § 1807.700 Notice of funds availability.

Each Applicant must submit a CMF Award Application in accordance with the applicable Notice of Funds Availability (NOFA) published in the Federal Register. The NOFA will advise prospective Applicants on how to obtain and complete an Application and will establish deadlines and other requirements. The NOFA will specify Application evaluation factors and any limitations, special rules, procedures, and restrictions for a particular Application round. After receipt of an Application, the CDFI Fund may request clarifying or technical information on the materials submitted as part of the Application.